Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Nivolumab

5

XII.c Pericardial effusion (w/wo tamponade)

1
Last update : 25/08/2016
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Avelumab
1
Durvalumab
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Lambrolizumab
4
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pembrolizumab
5

Publications

Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2018 Sep;41;329-331 2018 Sep
Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.
Clinical lung cancer 2018 Sep;19;e717-e720 2018 Sep
Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion.
Cardiology 2017;136;49-51 2017
Pericardial effusion with tamponade physiology induced by nivolumab.
International journal of cardiology 2016 Nov 01;222;613-614 2016 Nov 01

Powered by

  • ^
  • Contact
  • Cookies
  • About